Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
Yoon HA, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH 3rd, Wirchnianski AS, Paroder M, Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C, Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG, Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen S, Annam J, Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA, Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Gil MR, Fox AS, Chandran K, Wang T, Daily JP, Pirofski LA. Yoon HA, et al. Among authors: fehn k. JCI Insight. 2021 Feb 22;6(4):e142270. doi: 10.1172/jci.insight.142270. JCI Insight. 2021. PMID: 33476300 Free PMC article.
Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC.
Yoon HA, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH 3rd, Wirchnianski AS, Paroder M, Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C, Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG, Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen S, Annam J, Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA, Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Gil MR, Fox AS, Chandran K, Wang T, Daily JP, Pirofski LA. Yoon HA, et al. Among authors: fehn k. medRxiv [Preprint]. 2020 Dec 4:2020.12.02.20242909. doi: 10.1101/2020.12.02.20242909. medRxiv. 2020. PMID: 33300012 Free PMC article. Updated. Preprint.
Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting.
Thakkar A, Cui Z, Peeke SZ, Shah N, Pradhan K, Lombardo A, Khatun F, Mustafa J, De Castro A, Gillick K, Joseph F, Naik A, Rahman S, D'Aiello A, Elkind R, Sakalian S, Fehn K, Wright K, Abreu M, Townsend-Nugent L, Chambers N, Mathew R, Binakaj D, Nelson R, Palesi C, Paroder M, Uehlinger J, Wang Y, Shi Y, Zang X, Wang H, Nishimura C, Ren X, Steidl UG, Gritsman K, Janakiram M, Kornblum N, Derman O, Mantzaris I, Shastri A, Bartash R, Puius Y, McCort M, Goldfinger M, Bachier-Rodriguez L, Verma A, Braunschweig I, Sica RA. Thakkar A, et al. Among authors: fehn k. Stem Cell Investig. 2021 Sep 6;8:18. doi: 10.21037/sci-2021-008. eCollection 2021. Stem Cell Investig. 2021. PMID: 34631871 Free PMC article.
Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Verma A, Braunschweig I, Goldfinger M. Shapiro LC, et al. Among authors: fehn k. Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12. Bone Marrow Transplant. 2021. PMID: 33846558 No abstract available.
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, Abreu M, Elkind R, Fehn K, de Castro A, Wang Y, Derman O, Nelson R, Uehlinger J, Gritsman K, Sica RA, Kornblum N, Mantzaris I, Shastri A, Janakiram M, Goldfinger M, Verma A, Braunschweig I, Bachier-Rodriguez L. Abbasi A, et al. Among authors: fehn k. J Hematol Oncol. 2020 Jan 3;13(1):1. doi: 10.1186/s13045-019-0838-y. J Hematol Oncol. 2020. PMID: 31900191 Free PMC article.
Autologous stem cell transplantation in an older adult population.
Fedorov K, Jain T, Pradhan K, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Fehn K, De Castro A, Browne R, Abreu M, Binakaj D, Paroder M, Palesi C, Gritsman K, Sica RA, Kornblum N, Shastri A, Mantzaris I, Shah N, Verma A, Braunschweig I, Goldfinger M. Fedorov K, et al. Among authors: fehn k. Haematologica. 2022 Sep 1;107(9):2261-2265. doi: 10.3324/haematol.2022.281020. Haematologica. 2022. PMID: 35615933 Free PMC article. No abstract available.
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.
Shapiro LC, Thakkar A, Gali R, Gonzalez-Lugo JD, Bazarbachi AH, Rahman S, Pradhan K, Fehn K, Abreu M, Kornblum N, Gritsman K, Goldfinger M, Shastri A, Mantzaris I, Braunschweig I, Halmos B, Verma A, McCort M, Bachier-Rodriguez L, Sica RA. Shapiro LC, et al. Among authors: fehn k. Leuk Lymphoma. 2022 Oct;63(10):2484-2488. doi: 10.1080/10428194.2022.2074988. Epub 2022 May 20. Leuk Lymphoma. 2022. PMID: 35593019 No abstract available.
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P, Fehn K, Remy C, Jasra S, Kazemi M, Pradhan K, Kim M, Mantzaris I, Sica RA, Shah N, Goldfinger M, Kornblum N, Gritsman K, Braunschweig I, Steidl U, Will B, Shastri A, Verma A. Gonzalez-Lugo JD, et al. Among authors: fehn k. Clin Cancer Res. 2023 Jan 4;29(1):60-66. doi: 10.1158/1078-0432.CCR-22-1457. Clin Cancer Res. 2023. PMID: 36255372 Clinical Trial.
17 results